source
- Otsuka's Voyxact reduces kidney function decline in IgA nephropathy but falls short of expectations in Phase 3Otsuka reported Phase 3 trial results for its drug Voyxact in patients with IgA nephropathy, a chronic autoimmune kidney disease. In the study, patients receiving Voyxact experienced an annualized…
- Otsuka showcases kidney drug data; Pfizer cuts an AI dealVoyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…